Jul 25, 2024, 21:25
Elad Sharon: Another win for patients with ALL
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X:
“Another win for NCI, NCI CTEP Clinical Research, ECOG-ACRIN Cancer Research Group, but especially for patients with ALL! Amazing results with Amgen’s blinatumomab and for immunotherapy! Already approved by FDA Oncology...”
Source: Elad Sharon/X